Effect of preexisting immunity on an adenovirus vaccine vector: In vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo

Journal of Virology

Volumn 83, Issue 11, 2009, Pages 5567-5573

  Pichla Gollon, Susan L ^a,b   Lin, Shih Wen ^a   Hensley, Scott E ^a   Lasaro, Marcio O ^a   Herkenhoff Haut, Larissa ^a   Drinker, Mark ^a   Tatsis, Nia ^a   Gao, Guang Ping ^a   Wilson, James M ^a   Ertl, Hildegund C J ^a   Bergelson, Jeffrey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; VIRUS VACCINE; FC RECEPTOR; VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; GENE VECTOR; GENETICS; IMMUNOASSAY; IMMUNOLOGY; REPORTER GENE;

ADENOVIRIDAE; CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, REPORTER; GENETIC VECTORS; IMMUNOASSAY; MICE; MICE, INBRED BALB C; RECEPTORS, FC; TRANSGENES; VIRAL VACCINES;

EID: 66149084072     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00405-09     Document Type: Article

References (26)

1. Barouch, D. H., and G. J. Nabel. 2005. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16:149-156. (Pubitemid 40344207)
2. 1a. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893
3. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S. Dubey, D. M. Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D. Williams, W. Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long, W. Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X. Liang, R. Youil, M. Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W. Shiver. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313. (Pubitemid 36588400)
4. Fitzgerald, J. C., G. P. Gao, A. Reyes-Sandoval, G. N. Pavlakis, Z. Q. Xiang, A. P. Wlazlo, W. Giles-Davis, J. M. Wilson, and H. C. Ertl. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170:1416-1422. (Pubitemid 36139509)
5. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123. (Pubitemid 26087569)
6. Hensley, S. E., A. S. Cun, W. Giles-Davis, Y. Li, Z. Xiang, M. O. Lasaro, B. R. Williams, R. H. Silverman, and H. C. Ertl. 2007. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15:393-403. (Pubitemid 46111891)
7. Jiang, H., Z. Wang, D. Serra, M. M. Frank, and A. Amalfitano. 2004. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol. Ther. 10:1140-1142. (Pubitemid 39625257)
8. Kalyuzhniy, O., N. C. Di Paolo, M. Silvestry, S. E. Hofherr, M. A. Barry, P. L. Stewart, and D. M. Shayakhmetov. 2008. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 105:5483-5488.
9. Letvin, N. L. 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56:213-223. (Pubitemid 40299781)
10. Letvin, N. L., J. R. Mascola, Y. Sun, D. A. Gorgone, A. P. Buzby, L. Xu, Z. Y. Yang, B. Chakrabarti, S. S. Rao, J. E. Schmitz, D. C. Montefiori, B. R. Barker, F. L. Bookstein, and G. J. Nabel. 2006. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533. (Pubitemid 43865893)
11. 9a. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, and D. R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step study: a case-cohort analysis. Lancet 372:1894-1905
12. Pichla-Gollon, S. L., M. Drinker, X. Zhou, F. Xue, J. J. Rux, G. P. Gao, J. M. Wilson, H. C. Ertl, R. M. Burnett, and J. M. Bergelson. 2007. Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol. 81:1680-1689. (Pubitemid 46214443)
13. Pinto, A. R., J. C. Fitzgerald, G. P. Gao, J. M. Wilson, and H. C. Ertl. 2004. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 22:697-703. (Pubitemid 38114900)
14. Roberts, D. M., A. Nanda, M. J. Havenga, P. Abbink, D. M. Lynch, B. A. Ewald, J. Liu, A. R. Thorner, P. E. Swanson, D. A. Gorgone, M. A. Lifton, A. A. Lemckert, L. Holterman, B. Chen, A. Dilraj, A. Carville, K. G. Mansfield, J. Goudsmit, and D. H. Barouch. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
15. Reference deleted.
16. Roy, S., D. S. Clawson, R. Calcedo, C. Lebherz, J. Sanmiguel, D. Wu, and J. M. Wilson. 2005. Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology 333:207-214. (Pubitemid 40250106)
17. Roy, S., P. S. Shirley, A. McClelland, and M. Kaleko. 1998. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72:6875-6879. (Pubitemid 28324008)
18. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335. (Pubitemid 34087555)
19. Sumida, S. M., D. M. Truitt, A. A. Lemckert, R. Vogels, J. H. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, S. S. Jackson, D. A. Gorgone, M. A. Lifton, M. Essex, B. D. Walker, J. Goudsmit, M. J. Havenga, and D. H. Barouch. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185. (Pubitemid 40705685)
20. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76:519-529. (Pubitemid 24064172)
21. Tatsis, N., L. Tesema, E. R. Robinson, W. Giles-Davis, K. McCoy, G. P. Gao, J. M. Wilson, and H. C. Ertl. 2006. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13:421-429.
22. Varghese, R., Y. Mikyas, P. L. Stewart, and R. Ralston. 2004. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J. Virol. 78:12320-12332. (Pubitemid 39458751)
23. Waddington, S. N., J. H. McVey, D. Bhella, A. L. Parker, K. Barker, H. Atoda, R. Pink, S. M. Buckley, J. A. Greig, L. Denby, J. Custers, T. Morita, I. M. Francischetti, R. Q. Monteiro, D. H. Barouch, N. van Rooijen, C. Napoli, M. J. Havenga, S. A. Nicklin, and A. H. Baker. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
24. Wohlfart, C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328.
25. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667-2675. (Pubitemid 34184852)
26. Xiang, Z., Y. Li, A. Cun, W. Yang, S. Ellenberg, W. M. Switzer, M. L. Kalish, and H. C. Ertl. 2006. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12:1596-1599. (Pubitemid 44570909)